COPD & Asthma Capsule Franchise in Ahmedabad

Flutialfa Trio 100 Rota Capsule Supplier in Mumbai

Triple Therapy Respiratory Distributor in Delhi

COPD & Asthma Pharma Franchise in Bangalore

Flutialfa Trio Capsule Stockist in Hyderabad
Respiratory Therapy Capsule Manufacturer & Exporter in Chandigarh

Home/Products /vilanterol-25-fluticasone-100-umeclidinium-62-5-mcg-inhaler

Flutialfa Trio 100 Rota Capsule

Composition : Vilanterol 25 + Fluticasone 100 + Umeclidinium 62.5 mcg Inhaler

Dosage Form : Rota cap

Packaging Type : Inhaler

Packaging : 30 Doses

Price : ₹1/-

Please Contact For Best Price

Flutialfa Trio 100 Rota Capsule contains Vilanterol 25 mcg, Fluticasone 100 mcg, and Umeclidinium 62.5 mcg, a triple combination therapy designed for the long-term management of COPD and asthma.

Vilanterol is a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscles for bronchodilation, Umeclidinium is a long-acting muscarinic antagonist (LAMA) providing additional airway relaxation, and Fluticasone is an inhaled corticosteroid that reduces airway inflammation. Together, they help improve lung function, reduce exacerbations, and enhance symptom control.

Clinically, Flutialfa Trio 100 Rota Capsule is suitable for patients with moderate to severe COPD or asthma who require triple inhaled therapy for optimal disease control. The capsule formulation ensures consistent dosing and patient compliance.

From a business perspective, Flutialfa Trio 100 Rota Capsule strengthens the respiratory therapy segment, widely prescribed in pulmonology and respiratory clinics, offering steady demand, repeat prescriptions, and trusted clinical efficacy, making it a high-value addition for pharma partners.


Read More

About the Product

Flutialfa Trio 100 Rota Capsule contains Vilanterol 25 mcg, Fluticasone 100 mcg, and Umeclidinium 62.5 mcg, a triple combination therapy designed for the long-term management of COPD and asthma.

Vilanterol is a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscles for bronchodilation, Umeclidinium is a long-acting muscarinic antagonist (LAMA) providing additional airway relaxation, and Fluticasone is an inhaled corticosteroid that reduces airway inflammation. Together, they help improve lung function, reduce exacerbations, and enhance symptom control.

Clinically, Flutialfa Trio 100 Rota Capsule is suitable for patients with moderate to severe COPD or asthma who require triple inhaled therapy for optimal disease control. The capsule formulation ensures consistent dosing and patient compliance.

From a business perspective, Flutialfa Trio 100 Rota Capsule strengthens the respiratory therapy segment, widely prescribed in pulmonology and respiratory clinics, offering steady demand, repeat prescriptions, and trusted clinical efficacy, making it a high-value addition for pharma partners.


Common side effects may include headache, throat irritation, cough, dry mouth, hoarseness, or mild tremors. Rarely, palpitations, increased heart rate, urinary retention, or systemic corticosteroid effects may occur.

Flutialfa Trio 100 Rota Capsule is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults, particularly in patients requiring combination therapy to control airway inflammation, bronchoconstriction, and symptoms such as shortness of breath, wheezing, and frequent exacerbations.

Use Flutialfa Trio 100 Rota Capsule exactly as prescribed by a healthcare professional. Do not use for acute asthma or COPD attacks. Rinse the mouth after inhalation to prevent oral thrush. Avoid sudden discontinuation, and consult a doctor if side effects worsen or new symptoms appear.

Store at room temperature below 30°C in a dry place. Keep the capsules in their original packaging, protect from moisture and direct sunlight, and keep out of reach of children. Do not use beyond the expiry date.

Get in Touch